 |
| |
| Jul-12-18 | Upgrade |
Goldman |
Sell → Neutral |
|
|
| Jun-27-18 | Initiated |
Bernstein |
Mkt Perform |
$129 |
|
| Apr-23-18 | Reiterated |
Citigroup |
Neutral |
$146 → $134 |
|
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
| Oct-11-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-09-17 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Sep-25-17 | Initiated |
Citigroup |
Neutral |
$140 |
|
| Sep-20-17 | Downgrade |
Goldman |
Neutral → Sell |
$125 → $130 |
|
| Jul-21-17 | Downgrade |
BTIG Research |
Neutral → Sell |
$110 |
|
| Jul-21-17 | Downgrade |
Alembic Global Advisors |
Neutral → Underweight |
|
|
| Jul-20-17 | Resumed |
Credit Suisse |
Outperform |
$148 |
|
| Jul-05-17 | Reiterated |
Morgan Stanley |
Overweight |
$135 → $140 |
|
| May-18-17 | Reiterated |
Stifel |
Hold |
$124 → $128 |
|
|
|
| Dec-11-18 06:11PM | Cramer: Pick individual stocks with long-term growth stories in this 'treacherous' market CNBC |
| 04:15PM | Markets Right Now: Stock market ends mixed after a bumpy day Associated Press |
| 03:01PM | Today's Stock Market: Dow Jones Volatile After Trump Spars With Democratic Leaders Investor's Business Daily |
| 02:48PM | 12 Stocks You Should Never Sell Kiplinger |
| 11:56AM | Why Is Shopify Stock Holding Up While Others Cant Handle The Turmoil? InvestorPlace |
| 10:55AM | Will Wayfair Stock Remain a Safety Play During Market Turbulence? InvestorPlace |
| 09:51AM | Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800 Zacks |
| 07:37AM | Pennovation Center-based biotech startup raises $13M American City Business Journals |
| Dec-10-18 03:20PM | 19 Best Stocks to Buy for 2019 Kiplinger |
| 10:12AM | The Zacks Analyst Blog Highlights: Apple, DowDuPont, Exxon Mobil, Johnson & Johnson and Verizon Communications Zacks |
| 10:11AM | PFE Stock Has Broken Its Slump and Could Challenge Former Highs InvestorPlace |
| 07:00AM | Today's Research Reports on Trending Tickers: Johnson & Johnson and Bristol-Myers Squibb ACCESSWIRE |
| Dec-09-18 08:59PM | Is Johnson & Johnson (JNJ) A Good Stock According To Hedge Funds? Insider Monkey |
| 04:46PM | Here's Why BeiGene Stock Rose 21.7% in November Motley Fool |
| Dec-07-18 01:28AM | PRESS DIGEST-New York Times business news - Dec 7 Reuters |
| Dec-06-18 05:45PM | Johnson & Johnson (JNJ) Stock Moves -0.08%: What You Should Know Zacks |
| 05:19PM | J&J unit to pay $360 million to U.S. to resolve charity kickback probe Reuters |
| 05:11PM | Peninsula drug maker to pay $360M to settle Justice Department claims American City Business Journals |
| 03:30PM | 7 Dividend Titans Trading Like Growth Stocks InvestorPlace |
| 01:34PM | Houston cancer pharma co. begins Phase I trials after $6M Series B American City Business Journals |
| 01:05PM | Drug company Actelion to pay $360M in kickback probe Associated Press |
| 12:23PM | J&J unit to pay $360 million to U.S. to resolve charity kickback probe Reuters |
| 11:42AM | Can You Hide in Johnson and Johnson Stock Amid the Turmoil? InvestorPlace |
| 10:40AM | AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study Zacks |
| 12:15AM | [$$] Actelion Pharmaceuticals agrees to pay $360m in DoJ settlement Financial Times |
| Dec-05-18 03:53PM | Johnson & Johnson: An Excellent Business Selling at a Rational Price GuruFocus.com |
| 09:38AM | J&J's Blood Cancer Drugs Succeed in Label Expansion Studies Zacks |
| 09:14AM | Mylan Expands Recall of Valsartan to All Unexpired Lots Zacks |
| 08:17AM | Can Celgene and bluebird bio Survive a Two-Pronged Attack? Motley Fool |
| Dec-04-18 04:58PM | J&J Strikes Deal with argenx to Co-Develop Cancer Antibody Zacks |
| 04:18PM | P&G, Johnson & Johnson, Verizon Hold Strongest on Ugly Day for Dow Jones TheStreet.com |
| 03:38PM | Better Buy: Intuitive Surgical vs. Johnson & Johnson Motley Fool |
| 01:00PM | 10 Defensive Stocks to Protect Your Portfolio in 2019 InvestorPlace |
| 12:13PM | Johnson & Johnson CEO: Fix the Drug Pricing Process, But Not Too Much Meredith Videos |
| 10:37AM | JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial Reuters |
| 10:30AM | J&J's multiple myeloma drug reduces risk of death in late-stage study Reuters |
| 07:59AM | The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga |
| 07:19AM | Should You Be Worried About the Return of Big Pharma Deals? Motley Fool |
| 12:20AM | Amgen antibody shows promise in myeloma trial, gets FDA fast track Reuters |
| Dec-03-18 07:01PM | Jim Cramer: Don't Throw Away These Stocks TheStreet.com |
| 06:59PM | Cramer Remix: These recession-proof stocks are worth buying on a pullback CNBC |
| 04:09AM | Dutch firm argenx, J&J affiliate to collaborate on cancer therapy Reuters |
| Dec-02-18 10:02PM | J&J to Build Blood-Cancer Push With Controversial China Biotech Bloomberg |
| 10:31AM | [$$] Tech Companies Aren't the Only Ones Competing for Tech Workers The Wall Street Journal |
| 09:35AM | [$$] Tech Companies Aren't the Only Ones Competing for Tech Workers The Wall Street Journal |
| Dec-01-18 07:03AM | Top Biotech Stocks to Watch at ASH 2018 Motley Fool |
| Nov-30-18 09:56AM | Key Pharma Players With HIV Focus Ahead of World Aids Day Zacks |
| 09:05AM | [$$] Best-Run U.S. Companies of 2018---and How They Got That Way The Wall Street Journal |
| 08:56AM | 'Shark Tank' star Kevin OLeary reveals the type of stocks that should outperform in 2019 Yahoo Finance |
| 07:20AM | Report: Developing Opportunities within Unifirst, Royal Caribbean Cruises, Albemarle, Tableau Software, Huami, and Johnson & Johnson Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Nov-29-18 05:45PM | Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know Zacks |
| 04:47PM | Theravance Pipeline Strong, Plans Yupelri Launch by Year End Zacks |
| 08:10AM | 4 Big Pharma Stocks to Add to Your Portfolio in December Zacks |
| 07:57AM | The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture Zacks |
| Nov-28-18 07:20PM | [$$] New Parents Complain Amazon Baby-Registry Ads Are Deceptive The Wall Street Journal |
| 02:15PM | Campbell Soup aims at former Pinnacle Foods chief to take CEO job American City Business Journals |
| 10:20AM | Theravance's Respiratory Disease JAK Inhibitor Enters Phase I Zacks |
| 10:07AM | [$$] New Parents Complain Amazon Ads Are Deceptive The Wall Street Journal |
| 06:51AM | Time magazine names Tampa Bay-based invention among the best in 2018 American City Business Journals |
| Nov-27-18 04:35PM | Why Celgene's Blockbuster Cancer Drug Looks Safe For Now Investor's Business Daily |
| 12:25PM | Novartis's Alcon sees myopia epidemic driving sales growth Reuters |
| 10:34AM | 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far Zacks |
| 09:40AM | Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan Zacks |
| 07:44AM | The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer Zacks |
| Nov-26-18 06:35PM | Spinal-cord stimulators help some patients, injure others Associated Press |
| 05:37PM | AMAG's Label Expansion of Lead Products Raises Share Price Zacks |
| 09:33AM | Glaxo Inks Marketing Deal for Anaemia Candidate in Japan Zacks |
| 09:23AM | The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca Zacks |
| 08:00AM | Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference PR Newswire |
| 02:38AM | [$$] Microsoft: Wall Streets most resilient mega-cap? Financial Times |
| Nov-25-18 10:00AM | Stock Market Power Rankings: Save Us, Amazon Motley Fool |
| Nov-23-18 02:05PM | Bayer Hurts from Generic Competition & Pipeline Setbacks Zacks |
| 08:58AM | Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs Zacks |
| 08:10AM | Dow 30 Stock Roundup: Boeing to Supply 40 737 MAX 8 to Jeju Air, Pfizer Gets FDA Nod Zacks |
| 07:00AM | Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson ACCESSWIRE |
| Nov-22-18 09:16AM | Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days Zacks |
| 09:10AM | New Trends in Healthcare Push Stocks Higher: 5 Picks Zacks |
| 08:31AM | J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down Zacks |
| Nov-21-18 04:27PM | Stock Market Rally Dampened As Dow Gives Up 200-Point Gain Investor's Business Daily |
| 03:10PM | U.S. appeals court declines J&J bid to stop generic Zytiga sales Reuters |
| 03:01PM | 5 Top Stock Trades to Mull Over Thanksgiving InvestorPlace |
| 02:05PM | J&J Falls After Failing to Block Generic Zytiga Cancer Drug Bloomberg |
| 01:19PM | Johnson & Johnson's stock drops to pace Dow decliners after appeals court ruling on Zytiga disappoints MarketWatch |
| 11:15AM | Theravance JAK Inhibitor Enters Phase II for Crohn's Disease Zacks |
| 10:04AM | Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility Zacks |
| 09:36AM | Shire-Takeda Deal Gets Phase I Conditional European Approval Zacks |
| 08:16AM | Can Deal Interest Help Tesaro Recover? Motley Fool |
| 07:05AM | Today's Research Reports on Trending Tickers: Johnson & Johnson and Merck & Co. ACCESSWIRE |
| 05:00AM | Capitalism Is Working in the U.S. Bloomberg |
| Nov-20-18 03:52PM | Glaxo Seeks Label Expansion of Nucala in Pediatric Patients Zacks |
| 12:21PM | Here's What's Actually Working as the Market Sells Off: Charts TheStreet.com |
| 11:41AM | 5 Dow Stocks to Sell (And 2 to Buy) Kiplinger |
| 10:57AM | 5 Companies Hit 52-Week Highs GuruFocus.com |
| 08:29AM | The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings Benzinga |
| Nov-19-18 05:45PM | Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know Zacks |
| 05:15PM | Nasdaq Slides More Than 3% As These Dow Blue Chips Buck The Broad Sell-Off Investor's Business Daily |
| 04:41PM | Bulls Stampeded by Bears as FAANG Stocks Get Trampled TheStreet.com |
| 01:12PM | Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility TheStreet.com |
| 12:32PM | Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth TheStreet.com |
| 08:57AM | J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment Zacks |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Fasolo Peter | Exec VP, Chief HR Officer | Dec 04 | Option Exercise | 96.73 | 41,563 | 4,020,237 | 119,890 | Dec 06 05:27 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Dec 04 | Sale | 146.68 | 41,563 | 6,096,552 | 78,327 | Dec 06 05:27 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Dec 03 | Option Exercise | 94.12 | 125,132 | 11,777,919 | 203,459 | Dec 06 05:27 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Dec 03 | Sale | 146.32 | 125,132 | 18,308,689 | 78,327 | Dec 06 05:27 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Nov 23 | Option Exercise | 58.33 | 30,943 | 1,804,905 | 70,817 | Nov 27 06:56 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Nov 23 | Sale | 142.46 | 30,943 | 4,407,985 | 39,874 | Nov 27 06:56 PM | | Gorsky Alex | Chairman, CEO | Nov 16 | Option Exercise | 62.39 | 264,465 | 16,500,026 | 601,024 | Nov 16 07:44 PM | | Gorsky Alex | Chairman, CEO | Nov 16 | Sale | 145.96 | 264,465 | 38,600,968 | 336,559 | Nov 16 07:44 PM | | Kapusta Ronald A | Controller, CAO | Nov 08 | Sale | 145.15 | 8,441 | 1,225,200 | 17,284 | Nov 09 05:22 PM | | Duato Joaquin | Vice Chair, Exec Committee | Nov 07 | Option Exercise | 62.94 | 40,000 | 2,517,526 | 133,555 | Nov 09 05:20 PM | | Duato Joaquin | Vice Chair, Exec Committee | Nov 07 | Sale | 144.36 | 40,000 | 5,774,480 | 93,555 | Nov 09 05:20 PM | | Kapusta Ronald A | Controller, CAO | Sep 07 | Sale | 137.18 | 7,899 | 1,083,607 | 25,725 | Sep 11 03:53 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Aug 27 | Option Exercise | 58.33 | 29,000 | 1,691,570 | 59,124 | Aug 28 04:03 PM | | Sneed Michael E | EVP, Global Corp Aff & COO | Aug 27 | Sale | 134.80 | 29,000 | 3,909,084 | 30,124 | Aug 28 04:03 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Option Exercise | 90.44 | 155,342 | 14,049,130 | 357,906 | Feb 20 07:46 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Sale | 129.86 | 155,342 | 20,172,401 | 202,564 | Feb 20 07:46 PM | | Caruso Dominic J | Exec VP, Finance; CFO | Feb 09 | Option Exercise | 0.00 | 10,601 | 0 | 154,703 | Feb 13 06:54 PM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Feb 09 | Option Exercise | 0.00 | 9,812 | 0 | 78,348 | Feb 13 06:54 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 09 | Option Exercise | 0.00 | 5,830 | 0 | 69,992 | Feb 13 06:54 PM | | Gorsky Alex | Chairman, CEO | Feb 09 | Option Exercise | 0.00 | 33,165 | 0 | 285,990 | Feb 13 06:54 PM | | PETERSON SANDRA E | Exec VP, Group WW Chairman | Feb 09 | Option Exercise | 0.00 | 11,445 | 0 | 70,205 | Feb 13 06:54 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 09 | Option Exercise | 0.00 | 13,252 | 0 | 181,655 | Feb 13 06:55 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 09 | Option Exercise | 0.00 | 5,953 | 0 | 115,257 | Feb 13 06:55 PM | | Kapusta Ronald A | Controller, CAO | Feb 09 | Option Exercise | 0.00 | 2,702 | 0 | 32,666 | Feb 13 06:55 PM | | Mesquita Jorge S. | Exec VP, WW Chair, Consumer | Feb 02 | Option Exercise | 0.00 | 32,688 | 0 | 32,688 | Feb 06 04:21 PM |
|
|
|
|
|
|
